VisualSonics Vevo 2100

威视 Vevo 2100

• 批准号: 7794593
• 负责人: Burns C Blaxall
• 金额: $ 44.55万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7794593
• 关键词: Academic Medical Centers; Animal Experimentation; Animals; Arts; Cardiovascular system; Clinical and Translational Science Awards; Color; Commit; Discipline; Doctor of Philosophy; Faculty; Fostering; Functional disorder; Funding; Growth; Housing; Image; Individual; Lymphatic; Malignant Neoplasms; Medical center; Methods; Modality; Musculoskeletal Diseases; Nature; Operative Surgical Procedures; Perfusion; Physiologic pulse; Program Research Project Grants; Research; Research Design; Research Institute; Research Personnel; Resolution; Running; System; Time; Tissues; Training; Training Support; Transducers; Translational Research; Ultrasonography; Universities; base; cardiovascular imaging; cost; experience; fetal; hospice environment; imaging modality; instrument; instrumentation; interest; malformation; programs; public health relevance; reconstruction; skills

DESCRIPTION (provided by applicant): We are requesting funds to purchase a VisualSonics Vevo 2100 ultrasound imaging system for incorporation into the small animal Ultrasound Imaging Core at the University of Rochester Medical Center (URMC), an original awardee of the Clinical and Translational Science Award. VisualSonics is the only company in the world that manufactures high-resolution ultrasound imaging modalities targeted specifically to research animals. The newly introduced Vevo 2100 is a revolutionary, state of the art high-resolution ultrasound imaging system specifically designed for research animals. The Vevo 2100 has several enhancements over the earlier Vevo 770, including linear array transducers (probes), strain imaging, tissue doppler imaging, pulse wave Doppler, color Doppler, power Doppler, 3D reconstruction, contrast imaging, and contrast perfusion imaging. These new modalities provide unparalleled, revolutionary advancements regarding all aspects of non-invasive longitudinal cardiovascular imaging in particular, and small animal imaging in general. The Aab Cardiovascular Research Institute (Aab CVRI) at the University of Rochester Medical Center (URMC) currently has over three years experience operating a Vevo 770 in cardiovascular projects, including our Program Project Grant (B Berk, PI). This instrument is heavily used by investigators both within the Aab CVRI and throughout the URMC, and is near capacity. Due to the increased demand for non-invasive imaging of small animals, the current instrumentation within the URMC is no longer adequate. The Vevo 2100 provides unique imaging capabilities that are unavailable with the Vevo 770. To broaden access to the transformative nature of small animal ultrasound imaging, the current Vevo 770 will be upgraded using already committed institutional funds, and will be moved to the main URMC campus where it will broaden the availability of ultrasound imaging to a cadre of well funded investigators with well-established interest and expertise in ultrasound imaging. The availability of both machines will serve to expand the availability of high-resolution ultrasound imaging while at the same time expanding our imaging capabilities. The Vevo 2100 will housed in the Aab CVRI Surgery/Imaging Core under the hospice of the institutional Ultrasound Core. Within the Aab CVRI, the Vevo system is utilized, run and managed by a group of 18 well-funded PhD and MD investigators with extensive ultrasound imaging experience. In addition, well-trained support staff are in place to run the machine and to train new users of both the Vevo 2100 and Vevo 770. In summary, the transformative nature of the Vevo 2100 and expanded availability of small animal ultrasound imaging would not only maintain both the Aab CVRI and URMC at the cutting edge of translational research, but would further enhance our ability to attract the best and brightest cardiovascular investigators, produce sought-after trainees with cutting edge training and marketable skills, and foster continued, long-term growth of both the Aab CVRI and URMC funding and faculty, creating opportunities for numerous individual R01s and Program Project Grants across multiple disciplines. PUBLIC HEALTH RELEVANCE: Advanced small animal ultrasound imaging permits non-invasive tissue imaging, enabling enormous refinement in investigational methods that can also reduce the numbers of animals used. The Aab Cardiovascular Research Institute has an established ultrasound-based research program that will take full advantage of the VisualSonics Vevo 2100, a new state-of-the-art instrument. In a cost-effective expansion of ultrasound imaging to the entire University of Rochester Medical Center, the existing instrument will be upgraded and relocated to the main medical center campus, thus transforming both cardiovascular research and existing research programs in cancer, musculoskeletal disease, lymphatic dysfunction, and fetal malformation.

描述（由申请人提供）：我们正在申请资金购买VisualSonics Vevo 2100超声成像系统，用于纳入罗切斯特大学医学中心（URMC）的小动物超声成像核心，该中心是临床和转化科学奖的原始获奖者。VisualSonics是世界上唯一一家专门针对研究动物生产高分辨率超声成像模式的公司。新推出的Vevo 2100是一款革命性的、最先进的高分辨率超声成像系统，专为研究动物设计。与早期的Vevo 770相比，Vevo 2100具有多项增强功能，包括线阵探头（探头）、应变成像、组织多普勒成像、脉冲波多普勒、彩色多普勒、能量多普勒、3D重建、造影成像和造影灌注成像。这些新的模式提供了无与伦比的，革命性的进步，特别是在所有方面的非侵入性纵向心血管成像，并在一般的小动物成像。罗切斯特大学医学中心（URMC）的Aab心血管研究所（Aab CVRI）目前在心血管项目中拥有三年以上的Vevo 770操作经验，包括我们的计划项目资助（B Berk，PI）。该仪器被Aab CVRI和整个URMC的研究人员大量使用，并且接近容量。由于对小动物非侵入性成像的需求增加，URMC内的当前仪器不再足够。Vevo 2100提供了Vevo 770无法提供的独特成像功能。为了扩大小动物超声成像的变革性，目前的Vevo 770将使用已经承诺的机构资金进行升级，并将被转移到主要的URMC校园，在那里它将扩大超声成像的可用性，以获得资金充足的研究人员，他们对超声成像有着浓厚的兴趣和专业知识。这两台机器的可用性将有助于扩大高分辨率超声成像的可用性，同时扩大我们的成像能力。Vevo 2100将安置在机构超声核心收容所下的Aab CVRI外科/成像核心。在Aab CVRI内，Vevo系统由18名资金充足的博士和医学博士研究人员使用、运行和管理，他们具有丰富的超声成像经验。此外，我们还配备了训练有素的支持人员来运行机器，并培训Vevo 2100和Vevo 770的新用户。总之，Vevo 2100的变革性质和小动物超声成像的扩展可用性不仅将使Aab CVRI和URMC保持在转化研究的前沿，而且将进一步增强我们吸引最优秀和最聪明的心血管研究人员的能力，培养具有尖端培训和市场技能的抢手学员，并培养持续的，Aab CVRI和URMC资金和教师的长期增长，为众多个人R 01和跨多个学科的计划项目赠款创造了机会。 公共卫生关系：先进的小动物超声成像允许非侵入性组织成像，使研究方法得到极大的改进，也可以减少使用的动物数量。Aab心血管研究所拥有一个成熟的基于超声的研究项目，该项目将充分利用VisualSonics Vevo 2100，一种新的最先进的仪器。在一个具有成本效益的超声成像扩展到整个罗切斯特医学中心的大学，现有的仪器将升级和搬迁到主要的医疗中心校园，从而改变心血管研究和现有的研究计划在癌症，肌肉骨骼疾病，淋巴功能障碍和胎儿畸形。